Excessive Daytime SleepinessDS-MWT2NCT06872593
Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal
A study testing CPAP-withdrawal and Test Sequence in people with Excessive Daytime Sleepiness and Obstructive Sleep Apnea (OSA), run by Stefan Lakämper at 1 site in Switzerland.
Trial summary
In brief, the proposed study will evaluate a recently proposed naturalistic, driving simulation test to identify and measure sleepiness behind the wheel, one of the most underestimated causes of road accidents. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Excessive Daytime Sleepiness, Obstructive Sleep Apnea (OSA), CPAP Treatment
- What is being tested?
- CPAP-withdrawal and Test Sequence
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteSwitzerland
- Study dates
- 14 Jul 2025to 30 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Inclusion Criteria (OSA patients): adult drivers, diagnosed OSA, established CPAP-treatment regime, highly adherent and compliant within the last 6 months (>5h, >80% of days), at impaired eyesight with more than +/- 5 diopter or astigmatism, contact lenses are required (for eye tracking)
Inclusion criteria (healthy comparison croup): adult drivers, no declared psychiatric disorders, no declared sleep-related diagnosis, at impaired eyesight with more than +/- 5 diopter or astigmatism, contact lenses are required (for eye tracking)
Exclusion criteria (for both groups): sensibility to motion sickness (kinetosis, dizziness, etc. in 5 min screening drive), professional drivers (if working during the study period), inability to understand the study procedure for linguistic or cognitive reasons.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Division of Traffic Medicine, Institute of Forensic Medicine, University of Zurich
Zurich, ZRH, 8050
Stefan Lakämper, Dr. rer. nat., +41793789984, stefan.lakaemper@irm.uzh.ch
Veronika Gambin, +41797149386, nan.li@irm.uzh.ch
About this study
Official title: Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal - a Monocentric, Controlled, Randomized, Crossover Trial
In brief, the proposed study will evaluate a recently proposed naturalistic, driving simulation test to identify and measure sleepiness behind the wheel, one of the most underestimated causes of road accidents. The proposed test offers higher ecological validity and might complement somnological tests that are standard, but rarely performed. Thus, the test might provide traffic medicine and sonologists with an effective tool, that can also directly convey the risks of excessive daytime sleepiness to drivers and thus, in combination, effectively aid in traffic medicine's mandate to avoid preventable road fatalities.
Excessive daytime sleepiness (EDS) is a symptomatic condition resulting from too little or compromised sleep, caused by psycho-social stress (shiftwork, lifestyle) or medical conditions (obstructive sleep apnoea (OSA), narcolepsy). Driving with untreated EDS might lead to sleepy/drowsy driving and microsleep, which is considered to be one of the highest-ranking causes of road accidents. Sleepiness and its dangers on the wheel might subjectively not be registered by the affected drivers. Also, subjective sleepiness might not correlate with somnological measurements that are also crucial for legally determining the fitness to drive (FTD).
Read more
There exists a variety of partially complementary tools to evaluate the extent of EDS. Mean sleep latency obtained in the maintenance of wakefulness test (MWT) is widely, but not uniformly, considered to be one of the most objective measures to evaluate EDS, especially in the context of driving performance. However, there is inconsistent or insufficient evidence for MWTs to reliably predict the FTD in general, potentially as its result might be strongly influenced by motivation. Moreover, patients might not relate low mean MWT-latencies to their own and other's risks in traffic.
A need for improved tools to measure EDS was formulated. It remains open, whether the MWT should be replaced or complemented by, for example, future road-side metabolomics-tests detecting sleepiness in traffic or whether the MWT should be adapted to better convey a.) the risks of EDS in traffic and b.) its meaning for the determination of the FTD.
With this need in mind the investigators proposed furnishing the maintenance of wakefulness test with improved ecological validity to provide an improved tool for the assessment of the effect of excessive daytime sleepiness on the fitness to drive: recently published results from an exploratory feasibility study suggested it to be well possible to transfer the MWT-paradigm to a driving simulator (DS) with high user acceptance. The published result's implication and relevance was well received: the new test, DS-MWT, might complement somnological MWTs in pneumology and neurology. I might provide a naturalistic and relatable tool to determine EDS in traffic medicine, who is institutionally responsible for determining the FTD. This is also desirable, because prohibitively high cost - in time, money and instrumentation - often prevent a standard MWT in standard care of sleep-related medical conditions. Potentially, the use of the DS-MWT might help reduce the number of preventable road fatalities by more often identifying sleepy individuals before they get behind the wheel.
However, for this goal to be achieve, it remains to be evaluated whether the latencies obtained in classical or simulation conditions are comparable and whether obtained latencies actually reflect other clinical parameters of EDS relating to underlying medical conditions, such as for example OSA. This represents a significant gap of evidence for both medical experts in pneumology and traffic medicine, but also for affected drivers. This gap will be filled by systematically comparing classical and simulation-based MWTs by means of their resulting latencies. In a within-study setup of 36 highly adherent OSA-patients, experiments will be related to a main medical comparator, a ≥7-day continuous positive airway pressure (CPAP)-withdrawal (W) and subsequent -resumption or continuation (C), respectively. There will be a control group of 18 healthy participants for comparison.
- Conditions
- Excessive Daytime Sleepiness, Obstructive Sleep Apnea (OSA), CPAP Treatment, Driving Simulator Performance, Driving Impaired, CPAP
- Being tested
- CPAP-withdrawal, Test Sequence
- Keywords
- sleep, drowsy driving, sleepy driving, sleepiness behind the wheel, driving simulation, CPAP treatment, CPAP withdrawal, driving performance, sleep latency, maintenance of wakefulness test, MWT, microsleep, microsleep-like episodes, eye tracking, EEG-recording
- Medical subject headings
- Disorders of Excessive Somnolence, Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CPAP-withdrawalProcedure or surgery
7-day-long CPAP-withdrawal
Test SequenceDiagnostic test
Test Sequence M or D as specified in arm description
| Study group | Role | What they receive |
|---|---|---|
| OSA - W(first) + MD | Experimental | allocated OSA-participants will perform test sequence M -> D first after 7d CPAP-withdrawal, then after ≥7d CPAP. Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence |
| OSA - W(first) + DM | Experimental | allocated OSA-participants will perform test sequence D -> M first after 7d CPAP-withdrawal, then after ≥7d CPAP. Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence |
| OSA - C(first) + MD | Experimental | allocated OSA-participants will perform test sequence M -> D first after ≥7d CPAP, then after 7d CPAP-withdrawal. Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence |
| OSA - C(first) + DM | Experimental | allocated OSA-participants will perform test sequence D-> M first after ≥7d CPAP, then after 7d CPAP-withdrawal. Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence |
| Healthy control MD - DM | Other | healthy participants will perform test sequence M -> D first , then D -> M Receives: Diagnostic Test: Test Sequence |
| Healthy control DM - MD | Other | healthy participants will perform test sequence D -> M first , then M -> D. Receives: Diagnostic Test: Test Sequence |
What is being measured
The primary outcome is the main question the study is designed to answer.
significant difference between mean MWT- and DS-MWT-latencies
significant difference between mean latencies measured in classical maintenance of wakefulness test (MWT, M) and driving simulation-based maintenance of wakefulness test (DS-MWT, D) and DS-MWT-latencies.
Measured: MWT- and DS-MWT-latencies are measured in two consecutive days during CPAP-treatment and after 7 days CPAP-withdrawal (intervention) in randomized order.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2025
- Study start14 Jul 2025
- Primary completion30 Apr 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Excessive Daytime SleepinessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- monocentric, controlled, randomized, crossover trial, with two groups and four arms, plus a two-armed crossover control group
- Masking
- None (open label)
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stefan Lakämper
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital, Zürich
- Responsible party
- Sponsor-investigator, Stefan Lakämper, University of Zurich
- Investigators
- Stefan Lakämper, Dr. rer. nat., Principal investigator, University of ZurichEsther I Schwarz, PD, Dr. med., Principal investigator, University of ZurichKristina Keller, Dr. med., Principal investigator, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06872593
- Sponsor's protocol ID
- DS-MWT2
- Acronym
- DS-MWT2
- Status last verified
- Mar 2025
- First submitted
- 6 Mar 2025
- Last updated
- 17 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Results will be published in peer-reviewed journals. Anonymized raw data will be made available upon request.
Publications
Pisteljic M, Keller K, Lakamper S. Capturing sleep accidents in driving simulation as a promising tool to assess excessive daytime sleepiness with high ecological validity-a pilot study. Sleep. 2024 Aug 14;47(8):zsae110. doi: 10.1093/sleep/zsae110. No abstract available.
PubMed 38758109Gambin V, Li N, Schwarz EI, Keller K, Lakamper S. Validating a novel driving simulation-based MWT against the standard MWT in an OSA-cohort challenged by CPAP-withdrawal (DS-MWT2) - Protocol for a monocentric, controlled, randomized, crossover trial. PLoS One. 2026 Jul 9;21(7):e0341997. doi: 10.1371/journal.pone.0341997. eCollection 2026.
PubMed 42424269
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal - a Monocentric, Controlled, Randomized, Crossover Trial
- ClinicalTrials.gov ID
- NCT06872593
- Acronym / sponsor ID
- DS-MWT2 / DS-MWT2
- Conditions
- Excessive Daytime Sleepiness, Obstructive Sleep Apnea (OSA), CPAP Treatment, Driving Simulator Performance, Driving Impaired, CPAP
- Keywords
- sleep, drowsy driving, sleepy driving, sleepiness behind the wheel, driving simulation, CPAP treatment, CPAP withdrawal, driving performance
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Stefan LakämperUniversity, hospital or other
- Collaborators
- University Hospital, Zürich
- Study start
- 14 Jul 2025 (actual)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 12 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In brief, the proposed study will evaluate a recently proposed naturalistic, driving simulation test to identify and measure sleepiness behind the wheel, one of the most underestimated causes of road accidents. The proposed test offers higher ecological validity and might complement somnological tests that are standard, but rarely performed. Thus, the test might provide traffic medicine and sonologists with an effective tool, that can also directly convey the risks of excessive daytime sleepiness to drivers and thus, in combination, effectively aid in traffic medicine's mandate to avoid preventable road fatalities.
Excessive daytime sleepiness (EDS) is a symptomatic condition resulting from too little or compromised sleep, caused by psycho-social stress (shiftwork, lifestyle) or medical conditions (obstructive sleep apnoea (OSA), narcolepsy). Driving with untreated EDS might lead to sleepy/drowsy driving and microsleep, which is considered to be one of the highest-ranking causes of road accidents. Sleepiness and its dangers on the wheel might subjectively not be registered by the affected drivers. Also, subjective sleepiness might not correlate with somnological measurements that are also crucial for legally determining the fitness to drive (FTD).
There exists a variety of partially complementary tools to evaluate the extent of EDS. Mean sleep latency obtained in the maintenance of wakefulness test (MWT) is widely, but not uniformly, considered to be one of the most objective measures to evaluate EDS, especially in the context of driving performance. However, there is inconsistent or insufficient evidence for MWTs to reliably predict the FTD in general, potentially as its result might be strongly influenced by motivation. Moreover, patients might not relate low mean MWT-latencies to their own and other's risks in traffic.
A need for improved tools to measure EDS was formulated. It remains open, whether the MWT should be replaced or complemented by, for example, future road-side metabolomics-tests detecting sleepiness in traffic or whether the MWT should be adapted to better convey a.) the risks of EDS in traffic and b.) its meaning for the determination of the FTD.
With this need in mind the investigators proposed furnishing the maintenance of wakefulness test with improved ecological validity to provide an improved tool for the assessment of the effect of excessive daytime sleepiness on the fitness to drive: recently published results from an exploratory feasibility study suggested it to be well possible to transfer the MWT-paradigm to a driving simulator (DS) with high user acceptance. The published result's implication and relevance was well received: the new test, DS-MWT, might complement somnological MWTs in pneumology and neurology. I might provide a naturalistic and relatable tool to determine EDS in traffic medicine, who is institutionally responsible for determining the FTD. This is also desirable, because prohibitively high cost - in time, money and instrumentation - often prevent a standard MWT in standard care of sleep-related medical conditions. Potentially, the use of the DS-MWT might help reduce the number of preventable road fatalities by more often identifying sleepy individuals before they get behind the wheel.
However, for this goal to be achieve, it remains to be evaluated whether the latencies obtained in classical or simulation conditions are comparable and whether obtained latencies actually reflect other clinical parameters of EDS relating to underlying medical conditions, such as for example OSA. This represents a significant gap of evidence for both medical experts in pneumology and traffic medicine, but also for affected drivers. This gap will be filled by systematically comparing classical and simulation-based MWTs by means of their resulting latencies. In a within-study setup of 36 highly adherent OSA-patients, experiments will be related to a main medical comparator, a ≥7-day continuous positive airway pressure (CPAP)-withdrawal (W) and subsequent -resumption or continuation (C), respectively. There will be a control group of 18 healthy participants for comparison.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
- Model description
- monocentric, controlled, randomized, crossover trial, with two groups and four arms, plus a two-armed crossover control group
| Arm | Type | Receives |
|---|---|---|
| OSA - W(first) + MD | Experimental | Procedure: CPAP-withdrawal, Diagnostic Test: Test Sequenceallocated OSA-participants will perform test sequence M -> D first after 7d CPAP-withdrawal, then after ≥7d CPAP. |
| OSA - W(first) + DM | Experimental | Procedure: CPAP-withdrawal, Diagnostic Test: Test Sequenceallocated OSA-participants will perform test sequence D -> M first after 7d CPAP-withdrawal, then after ≥7d CPAP. |
| OSA - C(first) + MD | Experimental | Procedure: CPAP-withdrawal, Diagnostic Test: Test Sequenceallocated OSA-participants will perform test sequence M -> D first after ≥7d CPAP, then after 7d CPAP-withdrawal. |
| OSA - C(first) + DM | Experimental | Procedure: CPAP-withdrawal, Diagnostic Test: Test Sequenceallocated OSA-participants will perform test sequence D-> M first after ≥7d CPAP, then after 7d CPAP-withdrawal. |
| Healthy control MD - DM | Other | Diagnostic Test: Test Sequencehealthy participants will perform test sequence M -> D first , then D -> M |
| Healthy control DM - MD | Other | Diagnostic Test: Test Sequencehealthy participants will perform test sequence D -> M first , then M -> D. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CPAP-withdrawal7-day-long CPAP-withdrawal | Procedure or surgery | OSA - C(first) + DM, OSA - C(first) + MD, OSA - W(first) + DM, OSA - W(first) + MD |
| Test SequenceTest Sequence M or D as specified in arm description | Diagnostic test | Healthy control DM - MD, Healthy control MD - DM, OSA - C(first) + DM, OSA - C(first) + MD, OSA - W(first) + DM, OSA - W(first) + MD |
Primary outcome
significant difference between mean MWT- and DS-MWT-latencies
Time frame: MWT- and DS-MWT-latencies are measured in two consecutive days during CPAP-treatment and after 7 days CPAP-withdrawal (intervention) in randomized order.
significant difference between mean latencies measured in classical maintenance of wakefulness test (MWT, M) and driving simulation-based maintenance of wakefulness test (DS-MWT, D) and DS-MWT-latencies.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2025.
- Background: PubMed 38758109Pisteljic M, Keller K, Lakamper S. Capturing sleep accidents in driving simulation as a promising tool to assess excessive daytime sleepiness with high ecological validity-a pilot study. Sleep. 2024 Aug 14;47(8):zsae110. doi: 10.1093/sleep/zsae110. No abstract available.
- Derived from this study: PubMed 42424269Gambin V, Li N, Schwarz EI, Keller K, Lakamper S. Validating a novel driving simulation-based MWT against the standard MWT in an OSA-cohort challenged by CPAP-withdrawal (DS-MWT2) - Protocol for a monocentric, controlled, randomized, crossover trial. PLoS One. 2026 Jul 9;21(7):e0341997. doi: 10.1371/journal.pone.0341997. eCollection 2026.
- Swiss National Clinical Trial Prortall (SNCTP) Registration of DS-MWT2Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Results will be published in peer-reviewed journals. Anonymized raw data will be made available upon request.
Related trials for Excessive Daytime Sleepiness
Not yet recruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
RecruitingPhase 2/3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Narcolepsy Type 1, Narcolepsy Type 2
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Narcolepsy Type 1
RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
Narcolepsy Type 1
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stefan Lakämper, Dr. rer. nat. principal investigator
University of Zurich
Esther I Schwarz, PD, Dr. med. principal investigator
University of Zurich
Kristina Keller, Dr. med. principal investigator
University of Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CPAP-withdrawal and Test Sequence in people with Excessive Daytime Sleepiness and Obstructive Sleep Apnea (OSA), run by Stefan Lakämper at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stefan Lakämper, Dr. rer. nat. (+41793789984, stefan.lakaemper@irm.uzh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
significant difference between mean MWT- and DS-MWT-latencies (time frame: MWT- and DS-MWT-latencies are measured in two consecutive days during CPAP-treatment and after 7 days CPAP-withdrawal (intervention) in randomized order.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06872593, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2025.